Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018 (2018), Article ID 1052102, 10 pages
https://doi.org/10.1155/2018/1052102
Research Article

Vialinin A, an Edible Mushroom-Derived p-Terphenyl Antioxidant, Prevents VEGF-Induced Neovascularization In Vitro and In Vivo

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA

Correspondence should be addressed to Kota V. Ramana

Received 3 October 2017; Revised 6 December 2017; Accepted 13 December 2017; Published 6 February 2018

Academic Editor: Ryuichi Morishita

Copyright © 2018 Himangshu Sonowal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Chung and N. Ferrara, “Developmental and pathological angiogenesis,” Annual Review of Cell and Developmental Biology, vol. 27, no. 1, pp. 563–584, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Wang, C. Dabrosin, X. Yin et al., “Broad targeting of angiogenesis for cancer prevention and therapy,” Seminars in Cancer Biology, vol. 35, pp. S224–S243, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Hoff and K. K. Machado, “Role of angiogenesis in the pathogenesis of cancer,” Cancer Treatment Reviews, vol. 38, no. 7, pp. 825–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Zhao and A. A. Adjei, “Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor,” The Oncologist, vol. 20, no. 6, pp. 660–673, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. C. G. Willett, Y. Boucher, E. di Tomaso et al., “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer,” Nature Medicine, vol. 10, no. 2, pp. 145–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Ellis and D. J. Hicklin, “VEGF-targeted therapy: mechanisms of antitumour activity,” Nature Reviews Cancer, vol. 8, no. 8, pp. 579–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Kuhnert, J. R. Kirshner, and G. Thurston, “Dll4-Notch signaling as a therapeutic target in tumor angiogenesis,” Vascular Cell, vol. 3, no. 1, p. 20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Li, R. C. A. Sainson, C. E. Oon et al., “DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo,” Cancer Research, vol. 71, no. 18, pp. 6073–6083, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Bicknell and A. L. Harris, “Novel angiogenic signaling pathways and vascular targets,” Annual Review of Pharmacology and Toxicology, vol. 44, no. 1, pp. 219–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Cao, “Future options of anti-angiogenic cancer therapy,” Chinese Journal of Cancer, vol. 35, no. 1, p. 21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Garber, “Angiogenesis inhibitors suffer new setback,” Nature Biotechnology, vol. 20, no. 11, pp. 1067-1068, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. N. S. Vasudev and A. R. Reynolds, “Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions,” Angiogenesis, vol. 17, no. 3, pp. 471–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Loges, T. Schmidt, and P. Carmeliet, “Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates,” Genes & Cancer, vol. 1, no. 1, pp. 12–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Elice and F. Rodeghiero, “Side effects of anti-angiogenic drugs,” Thrombosis Research, vol. 129, pp. S50–S53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. N. P. Gullett, A. R. M. Ruhul Amin, S. Bayraktar et al., “Cancer prevention with natural compounds,” Seminars in Oncology, vol. 37, no. 3, pp. 258–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Sagar, D. Yance, and R. K. Wong, “Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 1,” Current Oncology, vol. 13, no. 1, pp. 14–26, 2006. View at Google Scholar
  18. A. Amin, H. Gali-Muhtasib, M. Ocker, and R. Schneider-Stock, “Overview of major classes of plant-derived anticancer drugs,” International Journal of Biomedical Science, vol. 5, no. 1, pp. 1–11, 2009. View at Google Scholar
  19. C. Xie, H. Koshino, Y. Esumi, S. Takahashi, K. Yoshikawa, and N. Abe, “Vialinin A, a novel 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenger from an edible mushroom in China,” Bioscience, Biotechnology, and Biochemistry, vol. 69, no. 12, pp. 2326–2332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Radulović, D. N. Quang, T. Hashimoto, M. Nukada, and Y. Asakawa, “Terrestrins A–G: p-Terphenyl derivatives from the inedible mushroom Thelephora terrestris,” Phytochemistry, vol. 66, no. 9, pp. 1052–1059, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Onose, C. Xie, Y. Q. Ye et al., “Vialinin A, a novel potent inhibitor of TNF-α production from RBL-2H3 cells,” Biological and Pharmaceutical Bulletin, vol. 31, no. 5, pp. 831–833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Q. Ye, H. Koshino, J.i. Onose, K. Yoshikawa, N. Abe, and S. Takahashi, “First total synthesis of vialinin A, a novel and extremely potent inhibitor of TNF-α production,” Organic Letters, vol. 9, no. 21, pp. 4131–4134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Q. Ye, J.i. Onose, N. Abe, H. Koshino, and S. Takahashi, “Design and synthesis of a vialinin A analog with a potent inhibitory activity of TNF-α production and its transformation into a couple of bioprobes,” Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 7, pp. 2385–7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Onose, Y. Yoshioka, Y. Q. Ye et al., “Inhibitory effects of vialinin A and its analog on tumor necrosis factor-alpha release and production from RBL-2H3 cells,” Cellular Immunology, vol. 279, no. 2, pp. 140–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Yoshioka, Y. Q. Ye, K. Okada et al., “Ubiquitin-specific peptidase 5, a target molecule of vialinin A, is a key molecule of TNF-α production in RBL-2H3 cells,” PLoS One, vol. 8, no. 12, article e80931, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Yoshioka, D. Namiki, M. Makiuchi et al., “Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 17, pp. 4237–4240, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Sonowal, P. B. Pal, K. Shukla, and K. V. Ramana, “Aspalatone prevents VEGF-induced lipid peroxidation, migration, tube formation, and dysfunction of human aortic endothelial cells,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 2769347, 11 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Tammali, A. B. M. Reddy, S. K. Srivastava, and K. V. Ramana, “Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo,” Angiogenesis, vol. 14, no. 2, pp. 209–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Weis and D. A. Cheresh, “Tumor angiogenesis: molecular pathways and therapeutic targets,” Nature Medicine, vol. 17, no. 11, pp. 1359–1370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. B. Pandey and S. I. Rizvi, “Plant polyphenols as dietary antioxidants in human health and disease,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 5, pp. 270–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Lu, M. Bhat, and S. Basu, “Plants and their active compounds: natural molecules to target angiogenesis,” Angiogenesis, vol. 19, no. 3, pp. 287–295, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Norikura, K. Fujiwara, T. Narita et al., “Anticancer activities of thelephantin O and vialinin A isolated from Thelephora aurantiotincta,” Journal of Agricultural and Food Chemistry, vol. 59, no. 13, pp. 6974–6979, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Ucuzian, A. A. Gassman, A. T. East, and H. P. Greisler, “Molecular mediators of angiogenesis,” Journal of Burn Care & Research, vol. 31, no. 1, pp. 158–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. B. N. Singh, S. Shankar, and R. K. Srivastava, “Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications,” Biochemical Pharmacology, vol. 82, no. 12, pp. 1807–1821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. O. Naksuriya, S. Okonogi, R. M. Schiffelers, and W. E. Hennink, “Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment,” Biomaterials, vol. 35, no. 10, pp. 3365–3383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. B. B. Aggarwal, S. C. Gupta, and B. Sung, “Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers,” British Journal of Pharmacology, vol. 169, no. 8, pp. 1672–1692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. J. L. Arbiser, N. Klauber, R. Rohan et al., “Curcumin is an in vivo inhibitor of angiogenesis,” Molecular Medicine, vol. 4, no. 6, pp. 376–383, 1998. View at Google Scholar
  38. J. H. Hong, K. S. Ahn, E. Bae, S. S. Jeon, and H. Y. Choi, “The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 2, pp. 147–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Garvin, K. Ollinger, and C. Dabrosin, “Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo,” Cancer Letters, vol. 231, no. 1, pp. 113–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Brakenhielm, R. Cao, and Y. Cao, “Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes,” The FASEB Journal, vol. 15, no. 10, pp. 1798–1800, 2001. View at Publisher · View at Google Scholar
  41. M. Ushio-Fukai and Y. Nakamura, “Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy,” Cancer Letters, vol. 266, no. 1, pp. 37–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. Y.-W. Kim and T. V. Byzova, “Oxidative stress in angiogenesis and vascular disease,” Blood, vol. 123, no. 5, pp. 625–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. X. Zhou, G. G. Yue, M. Liu et al., “Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling,” Oncotarget, vol. 7, no. 50, pp. 82820–82835, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Lu and S. Basu, “The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions,” Scientific Reports, vol. 5, no. 1, article 9642, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. U. C. Yadav and K. V. Ramana, “Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes,” Oxidative Medicine and Cellular Longevity, vol. 2013, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. S. P. Tabruyn and A. W. Griffioen, “NF-κB: a new player in angiostatic therapy,” Angiogenesis, vol. 11, no. 1, pp. 101–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. S. P. Tabruyn and A. W. Griffioen, “A new role for NF-κB in angiogenesis inhibition,” Cell Death and Differentiation, vol. 14, no. 8, pp. 1393–1397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Thal and R. KishoreJ. L. Mehta and N. S. Dhalla, “Role of cytokines in angiogenesis: turning it on and off,” in Biochemical Basis and Therapeutic Implications of Angiogenesis, pp. 47–61, Springer New York, New York, NY, USA, 2013. View at Publisher · View at Google Scholar
  49. G. Neufeld and O. Kessler, “Pro-angiogenic cytokines and their role in tumor angiogenesis,” Cancer Metastasis Reviews, vol. 25, no. 3, pp. 373–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Mehrad, M. P. Keane, and R. M. Strieter, “Chemokines as mediators of angiogenesis,” Thrombosis and Haemostasis, vol. 97, no. 5, pp. 755–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Albini, F. Tosetti, R. Benelli, and D. M. Noonan, “Tumor inflammatory angiogenesis and its chemoprevention,” Cancer Research, vol. 65, no. 23, pp. 10637–10641, 2005. View at Publisher · View at Google Scholar · View at Scopus